These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920 [TBL] [Abstract][Full Text] [Related]
8. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Mohty M; Boiron JM; Damaj G; Michallet AS; Bay JO; Faucher C; Perreau V; Bilger K; Coso D; Stoppa AM; Tabrizi R; Gastaut JA; Michallet M; Maraninchi D; Blaise D Bone Marrow Transplant; 2004 Jul; 34(1):77-84. PubMed ID: 15133485 [TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394 [TBL] [Abstract][Full Text] [Related]
10. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study. Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493 [TBL] [Abstract][Full Text] [Related]
11. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. Bruno B; Sorasio R; Patriarca F; Montefusco V; Guidi S; Busca A; Scimé R; Console G; Milone G; Marotta G; Dominietto A; Giaccone L; Rotta M; Falda M; Bacigalupo A; Bosi A; Corradini P; Fanin R; Pollichieni S; Boccadoro M; Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132 [TBL] [Abstract][Full Text] [Related]
12. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation. Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846 [TBL] [Abstract][Full Text] [Related]
13. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis. Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931 [TBL] [Abstract][Full Text] [Related]
14. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. Shimoni A; Hardan I; Ayuk F; Schilling G; Atanackovic D; Zeller W; Yerushalmi R; Zander AR; Kroger N; Nagler A Cancer; 2010 Aug; 116(15):3621-30. PubMed ID: 20564132 [TBL] [Abstract][Full Text] [Related]
15. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906 [TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR; Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337 [TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience. Strullu M; Rialland F; Cahu X; Brissot E; Corradini N; Thomas C; Blin N; Rialland X; Méchinaud F; Mohty M Eur J Haematol; 2012 Jun; 88(6):504-9. PubMed ID: 22372430 [TBL] [Abstract][Full Text] [Related]
18. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. Todisco E; Castagna L; Sarina B; Mazza R; Anastasia A; Balzarotti M; Banna G; Tirelli U; Soligo D; Santoro A Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967 [TBL] [Abstract][Full Text] [Related]
19. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218 [TBL] [Abstract][Full Text] [Related]
20. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W; J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]